Statistics for Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial
Total visits
| views | |
|---|---|
| Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial | 62 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:d69914e2-88a8-4544-9f90-9d3eb1455a0a | 82 |
| Burns2021Infliximab-CCBYNCND.pdf | 74 |
| java.util.UUID:e788af0e-5415-4f85-b288-6d72b948ea33 | 14 |
| java.util.UUID:39d49afd-c491-4ce6-8e6b-5dc8c6557789 | 6 |
Top country views
| views | |
|---|---|
| United States | 51 |
| France | 2 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 41 |
| Ann Arbor | 3 |
| Mount Laurel | 2 |
| Paris | 2 |
| Cambridge | 1 |
| Seremban | 1 |
| Washington | 1 |